Compare CCO & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCO | PGEN |
|---|---|---|
| Founded | 1995 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2005 | 2013 |
| Metric | CCO | PGEN |
|---|---|---|
| Price | $2.41 | $3.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $2.12 | ★ $8.33 |
| AVG Volume (30 Days) | ★ 4.7M | 4.5M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 110.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,604,140,000.00 | $230,981,000.00 |
| Revenue This Year | $5.35 | $1,115.92 |
| Revenue Next Year | $4.26 | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.57 | N/A |
| 52 Week Low | $1.00 | $1.38 |
| 52 Week High | $2.43 | $5.47 |
| Indicator | CCO | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 38.10 |
| Support Level | $2.37 | $3.49 |
| Resistance Level | $2.41 | $4.40 |
| Average True Range (ATR) | 0.01 | 0.24 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 100.00 | 12.40 |
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.